{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:37Z","timestamp":1791105697491,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T00:00:00Z","timestamp":1301875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In Parkinson's disease (PD), dyskinesia develops following long\u2010term treatment with 3,4\u2010dihydroxyphenylalanine (\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the clinic (naltrexone and naloxone), although without success. In the current study, ADL5510, a novel, orally active opioid antagonist with mu opioid receptor selectivity, was examined in\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa\u2010treated 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP) macaques. Antidyskinetic effects were compared with those of naltrexone. Parkinsonian monkeys with established\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa\u2010induced dyskinesia (LID) received acute challenges with\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa (subcutaneously) in combination with either vehicle, ADL5510 (0.1, 1, 3 or 10 mg\/kg by mouth), or naltrexone (1, 3, or 10 mg\/kg subcutaneously). Following treatments, behavior was monitored for 6 hours. Parameters assessed were total activity, parkinsonism, and dyskinesia. ADL5510 (1, 3, and 10 mg\/kg) reduced activity and LID (chorea and dystonia) without affecting the antiparkinsonian benefits of\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa. The antidyskinetic effect of ADL5510 showed a U\u2010shaped dose\u2013response. It was inactive at 0.1 mg\/kg, efficacious at 1 and 3 mg\/kg (72% and 40% reductions, respectively), and then less effective at 10 mg\/kg. The quality of ON time produced by\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa was improved, as indicated by a reduction in the percentage of ON time spent experiencing disabling dyskinesia (70% and 61% reductions with 1 and 3 mg\/kg, respectively, compared with\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa). Naltrexone, in contrast, did not alleviate LID or affect the antiparkinsonian actions of\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa. Mu\u2010selective opioid antagonists have the potential to form the basis of novel antidyskinetic therapies for PD. \u00a9 2011 Movement Disorder Society\n                  <\/jats:p>","DOI":"10.1002\/mds.23631","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T17:59:46Z","timestamp":1301939986000},"page":"1225-1233","source":"Crossref","is-referenced-by-count":56,"title":["The selective mu\u2010opioid receptor antagonist adl5510 reduces levodopa\u2010induced dyskinesia without affecting antiparkinsonian action in mptp\u2010lesioned macaque model of Parkinson's disease"],"prefix":"10.1002","volume":"26","author":[{"given":"James B.","family":"Koprich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Le Bourdonnec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Dolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"DeHaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"DeHaven\u2010Hudkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,4]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-33328-0_1"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21743"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000310812.43352.66"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20988"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20324"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(82)90186-X"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1229"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)90102-7"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199911)46:5<732::AID-ANA8>3.0.CO;2-Q"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/121.3.527"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)91252-3"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6996"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00064-5"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2003.09.001"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.06.038"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2000.0372"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7727"},{"issue":"4","key":"e_1_2_7_23_2","first-page":"S154","article-title":"Neuroimaging of dyskinesia","volume":"47","author":"Brooks DJ","year":"2000","journal-title":"Ann Neurol."},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420508"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10693"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.4.554"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090410"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.02.009"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.01.006"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00249-1"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.02.002"},{"key":"e_1_2_7_32_2","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1523\/JNEUROSCI.21-12-04436.2001","article-title":"Endomorphin\u20101: induction of motor behavior and lack of receptor desensitization","volume":"21","author":"Mehta A","year":"2001","journal-title":"J Neurosci"},{"key":"e_1_2_7_33_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-3565(24)38161-3","article-title":"Loperamide (ADL 2\u20131294), an opioid antihyperalgesic agent with peripheral selectivity","volume":"289","author":"DeHaven\u2010Hudkins DL","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.166629"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702523"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.70020626.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0731058.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N\u2010methyl\u2010D\u2010aspartate receptor subtype selective antagonists on dyskinesias in levodopa\u2010treated 1\u2010methyl\u20104\u2010phenyl\u2010tetrahydropyridine monkeys","volume":"290","author":"Blanchet PJ","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20345"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199702100-00018"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21475"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0251-7"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22095"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23040"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.5.577"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313834.22171.17"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390505"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(02)00011-5"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3010fje"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23631","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23631","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:29:17Z","timestamp":1760959757000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,4]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1002\/mds.23631"],"URL":"https:\/\/doi.org\/10.1002\/mds.23631","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9987957.10722055","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,4]]}}}